The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀Positive FDA Pre-NDA Feedback Supports Rolling NDA ...

PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U ...

The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the Fir ...

Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...

Exelixis (NasdaqGS:EXEL) reported that the FDA has accepted its New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The filing is based on phase 3 STELLAR-303 ...

Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read ...

Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript February 10, 2026 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.94, expectations were $0.77. Operator: Good day, ladies ...

With an off day in between performing at Climate Pledge Arena last August, Lady Gaga ran down to Burien to film a commercial ...

The non-disclosure agreements follow a pattern of secrecy within the technology industry, experts said, amid a public outcry ...

KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...

The existence of Non- Disclosure Agreements is no secret but there’s much more to these than ensuring confidentiality, says Austin Lafferty ...

Visakhapatnam: After a long wait, the Centre gives a green signal to the Vizag metro rail project. Aimed at improving urban mobility in Visakhapatnam by minimising traffic congestion and ...